ATOS Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of -- compared to Atossa Therapeutics, Inc.'s net margin of 12.65%. Atossa Therapeutics, Inc.'s return on equity of -47.46% beat Electromed, Inc.'s return on equity of 18.89%.

Atossa Therapeutics, Inc. has a consensus price target of $5.75, signalling upside risk potential of 737.83%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 25.31%. Given that Atossa Therapeutics, Inc. has higher upside potential than Electromed, Inc., analysts believe Atossa Therapeutics, Inc. is more attractive than Electromed, Inc..

Atossa Therapeutics, Inc. has a beta of 0.950, which suggesting that the stock is 4.956% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

Atossa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atossa Therapeutics, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Atossa Therapeutics, Inc. quarterly revenues are --, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Atossa Therapeutics, Inc.'s net income of -$8.7M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Atossa Therapeutics, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 30.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atossa Therapeutics, Inc. is -- versus 3.83x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Myomo, Inc. has a net margin of -- compared to Atossa Therapeutics, Inc.'s net margin of -36.3%. Atossa Therapeutics, Inc.'s return on equity of -47.46% beat Myomo, Inc.'s return on equity of -68.35%.

Atossa Therapeutics, Inc. has a consensus price target of $5.75, signalling upside risk potential of 737.83%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 390.2%. Given that Atossa Therapeutics, Inc. has higher upside potential than Myomo, Inc., analysts believe Atossa Therapeutics, Inc. is more attractive than Myomo, Inc..

Atossa Therapeutics, Inc. has a beta of 0.950, which suggesting that the stock is 4.956% less volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.

Atossa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atossa Therapeutics, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.

Atossa Therapeutics, Inc. quarterly revenues are --, which are smaller than Myomo, Inc. quarterly revenues of $10.1M. Atossa Therapeutics, Inc.'s net income of -$8.7M is lower than Myomo, Inc.'s net income of -$3.7M. Notably, Atossa Therapeutics, Inc.'s price-to-earnings ratio is -- while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atossa Therapeutics, Inc. is -- versus 1.00x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -- compared to Atossa Therapeutics, Inc.'s net margin of -862.39%. Atossa Therapeutics, Inc.'s return on equity of -47.46% beat VolitionRX Ltd.'s return on equity of --.

Atossa Therapeutics, Inc. has a consensus price target of $5.75, signalling upside risk potential of 737.83%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 773.02%. Given that VolitionRX Ltd. has higher upside potential than Atossa Therapeutics, Inc., analysts believe VolitionRX Ltd. is more attractive than Atossa Therapeutics, Inc..

Atossa Therapeutics, Inc. has a beta of 0.950, which suggesting that the stock is 4.956% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Atossa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atossa Therapeutics, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Atossa Therapeutics, Inc. quarterly revenues are --, which are smaller than VolitionRX Ltd. quarterly revenues of $627.3K. Atossa Therapeutics, Inc.'s net income of -$8.7M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, Atossa Therapeutics, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atossa Therapeutics, Inc. is -- versus 17.27x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -- compared to Atossa Therapeutics, Inc.'s net margin of 3.93%. Atossa Therapeutics, Inc.'s return on equity of -47.46% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Atossa Therapeutics, Inc. has a consensus price target of $5.75, signalling upside risk potential of 737.83%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 92.8%. Given that Atossa Therapeutics, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Atossa Therapeutics, Inc. is more attractive than Xtant Medical Holdings, Inc..

Atossa Therapeutics, Inc. has a beta of 0.950, which suggesting that the stock is 4.956% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Atossa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atossa Therapeutics, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Atossa Therapeutics, Inc. quarterly revenues are --, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Atossa Therapeutics, Inc.'s net income of -$8.7M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Atossa Therapeutics, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 76.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atossa Therapeutics, Inc. is -- versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.